Comparative Pharmacology
Head-to-head clinical analysis: ACANYA versus EVOCLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACANYA versus EVOCLIN.
ACANYA vs EVOCLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Apply a pea-sized amount to the entire face once daily in the evening, topical.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
None Documented
None Documented
Clindamycin: after topical application, terminal half-life is approximately 2-3 hours in serum, but clinical relevance is minimal due to low systemic levels. Benzoyl peroxide metabolites have a half-life of ~1-2 hours. The clinical effect is primarily local with sustained antimicrobial and keratolytic activity.
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
Acanya (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% gel) is a fixed-dose combination applied topically. Systemic absorption is minimal. Clindamycin: <0.1% of applied dose excreted renally as parent and metabolites. Benzoyl peroxide: metabolized to benzoic acid, which is conjugated and excreted renally; <5% of applied dose appears in urine. Fecal excretion is negligible.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic